Bristol diabetes pill tied to certain cancers

A new type of diabetes pill being developed by Bristol Myers Squibb and AstraZeneca was effective in a two-year study but more bladder and breast cancers have been found in patients treated with the drug.

In all studies so far completed, 1.4 percent of patients treated with dapagliflozin developed some type of cancer, compared with 1.3 percent of control group patients, said Elisabeth Bjork, vice president of development for dapagliflozin at AstraZeneca.

Nine bladder cancers have been

Bristol diabetes pill tied to certain cancers